| Name | Title | Contact Details |
|---|
MediPharm Labs was created in 2015 by a handful of industry experts in Ontario. With the medicinal benefits of cannabis firmly established – and with a global patient market demanding quality cannabis oil – MediPharm Labs was born. While initially exploring options to cultivate cannabis plant, MediPharm Labs came to recognize the opportunity for a select focus on cannabis concentrates. MediPharm Labs set out to master this area of production, and rely on the many cultivating experts to provide quality raw materials. In 2016, MediPharm labs submitted an application to Health Canada for approval to distribute medicinal cannabis oil. Proudly, MediPharm Labs was one of the first Licensed Producer applications in history to apply for license that did not include the cultivation of cannabis. The key to MediPharm Labs` unrivaled quality is our best possible use of modern technology and innovative extraction techniques. MediPharm Labs produces cannabis oil that is pharmaceutical grade and and meets the specific quality and purity requirements. The team behind MediPharm Labs have proven industry experience in the areas of pharmaceutical extraction, processing and quality assurance. In 2018, MediPharm Labs is gearing up to commence distribution to our Health Canada approved business partners and make history. The response has been enormous, positive and heartening. Medicinal cannabis has arrived – and through our partners we will provide patients with access to pure, consistent and safe cannabis oil. MediPharm Labs commenced construction of a world-class extraction facility in Australia in June 2018. MediPharm Labs Australia is a subsidiary of MediPharm Labs Inc. and the companies` first expansion outside of Canada. MediPharm Labs Australia completed its application process with the federal Office of Drug Control in February 2018 to extract and import medical cannabis products in Australia.
Imprimis Pharmaceuticals is a pharmaceutical company dedicated to delivering high quality and innovative medicines to physicians and patients at affordable prices. We are pioneering a new commercial pathway in the pharmaceutical industry, using compounding pharmacies for the formulation and distribution of high quality, proprietary formulations that are supported by the clinical experience of physicians and their patients. We are focused on ophthalmology and urology drug therapies; however we also sell other formulations outside of our core ophthalmology and urology therapeutic areas. All of our innovative drug formulations are born from the clinical experience of physician prescribers and pharmacist formulators. We believe our unique business model provides us with the opportunity to address unmet patient needs while delivering safe, near-term and affordable medical solutions to Americans. We have made tremendous progress since the launch of our ophthalmology business and our Go Dropless™ educational campaign in April 2014. Our ophthalmology business is disrupting the billion dollar eye drop market as physicians are adopting Dropless Therapy™ for their patients. We recently announced the availability of our LessDrops™ proprietary topical combination eye drops for post LASIK and other ocular surgeries. During first quarter 2015, we launched our urology business, entering the multi-billion dollar interstitial cystitis (IC) market. In connection with our urology launch, we will commercialize our patented Hep-Lido-A formulation and promote the Defeat IC™ educational campaign focused on medical practitioners and the estimated ten million women and men in the U.S. chronically affected by IC and PBS. We are committed to customer relations, highest quality standards, accessible innovation and solving the unmet needs in the markets we serve. We are delivering on the promise of our unique model and look forward to continuing to serve the needs of our customers with additional novel drug therapies in our product portfolio, and in turn grow our business. Our hope is that through the success of our business we will reduce healthcare costs and provide Americans access to high quality, novel and previously unavailable medicines.
Edgewise Therapeutics is a biotechnology company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury with disease. Edgewise recently closed it`s Series B financing round which will support the advancement of Edgewise Therapeutic`s lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the company`s pipeline. The company`s leadership team has founded multiple biotechnology startups, several of which have gone on to become publicly-traded companies and brings to bear a depth of experience in drug discovery, development and commercialization.
Global Medical Institutes is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
GFS Chemicals is a Powell, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.